Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
97 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Atrial Fibrillation - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Atrial Fibrillation - Pipeline Review, H2 2016', provides an overview of the Atrial Fibrillation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Atrial Fibrillation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Atrial Fibrillation - The report reviews pipeline therapeutics for Atrial Fibrillation by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Atrial Fibrillation therapeutics and enlists all their major and minor projects - The report assesses Atrial Fibrillation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Atrial Fibrillation Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Atrial Fibrillation - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Atrial Fibrillation pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Atrial Fibrillation Overview 9 Therapeutics Development 10 Pipeline Products for Atrial Fibrillation - Overview 10 Pipeline Products for Atrial Fibrillation - Comparative Analysis 11 Atrial Fibrillation - Therapeutics under Development by Companies 12 Atrial Fibrillation - Therapeutics under Investigation by Universities/Institutes 13 Atrial Fibrillation - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Atrial Fibrillation - Products under Development by Companies 17 Atrial Fibrillation - Products under Investigation by Universities/Institutes 19 Atrial Fibrillation - Companies Involved in Therapeutics Development 20 ARCA biopharma, Inc. 20 AstraZeneca Plc 21 Bristol-Myers Squibb Company 22 Cardiome Pharma Corp. 23 Daiichi Sankyo Company, Limited 24 Dong-A Socio Holdings Co. Ltd. 25 Gilead Sciences, Inc. 26 Laboratoires Pierre Fabre SA 27 Nissan Chemical Industries, Ltd. 28 OMEICOS Therapeutics GmbH 29 Otsuka Holdings Co., Ltd. 30 Xention Limited 31 Atrial Fibrillation - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Target 33 Assessment by Mechanism of Action 35 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Drug Profiles 41 AFC-1 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 BMS-919373 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 bucindolol hydrochloride - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 edoxaban tosylate - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 F-373280 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 flecainide acetate - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Gene Therapy for Atrial Fibrillation - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 GS-967 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 NIP-151 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 OMT-28 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 OPC-108459 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Small Molecule to Block Calcium-Activated Potassium Channel for Atrial Fibrillation - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 Small Molecules to Block GIRK for Atrial Fibrillation - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Small Molecules to Block Voltage Gated Sodium Channel for Atrial Fibrillation - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 STP-023725 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 vernakalant hydrochloride - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 XEN-R0702 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 XEND-0103 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 XENR-0703 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 XENR-0706 - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 Atrial Fibrillation - Dormant Projects 78 Atrial Fibrillation - Discontinued Products 83 Atrial Fibrillation - Product Development Milestones 84 Featured News & Press Releases 84 May 11, 2016: Cardiome Announces Publication of Spanish Emergency Department BRINAVESS Study 84 May 02, 2016: New drug more effective in treating atrial fibrillation 84 Mar 31, 2016: Cardiome Announces Publication of Independent Study Comparing BRINAVESS to IBUTILIDE in Patients with Recent-Onset Atrial Fibrillation 85 Mar 24, 2016: Daiichi Sankyo to Present Findings From New Subgroup Analyses of Once-Daily SAVAYSA(edoxaban) in NVAF and VTE at ACC's 65th Annual Scientific Session 85 Jan 27, 2016: Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA 87 Jan 13, 2016: Cardiome announces filing of marketing authorization application for intravenous vernakalant in the Kingdom Of Saudi Arabia 87 Dec 22, 2015: Cardiome Files New Drug Submission Seeking Canadian Approval Of Intravenous Vernakalant 87 Nov 02, 2015: Daiichi Sankyo, Inc. Announces New Subgroup Analyses of Once-Daily SAVAYSA in Patients with Non-Valvular Atrial Fibrillation Will Be Presented at AHA Scientific Sessions 2015 88 Nov 02, 2015: OMEICOS Receives BMBF Research Grant to Advance its Novel Approach to Treat Atrial Fibrillation 89 Sep 23, 2015: UK's NICE recommends once-daily LIXIANA (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation 89 Aug 10, 2015: United Kingdom Department of Health Sets BRINAVESS Pricing 91 Jul 24, 2015: Cardiome Partner Eddingpharm to Initiate BRINAVESS Phase I Study in China 91 Jul 09, 2015: New Therapy to Help Heart Rhythm Patients Means Doctors are "Spoilt for Choice" 91 Jun 25, 2015: Daiichi Sankyo's Once-Daily LIXIANA (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE 93 Jun 12, 2015: Independent Study Finds Intravenous Vernakalant Facilitates Electrical Cardioversion in Patients with Cardioversion Resistant Atrial Fibrillation 94 Appendix 96 Methodology 96 Coverage 96 Secondary Research 96 Primary Research 96 Expert Panel Validation 96 Contact Us 96 Disclaimer 97
List of Tables
Number of Products under Development for Atrial Fibrillation, H2 2016 10 Number of Products under Development for Atrial Fibrillation - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Number of Products under Investigation by Universities/Institutes, H2 2016 13 Comparative Analysis by Late Stage Development, H2 2016 14 Comparative Analysis by Clinical Stage Development, H2 2016 15 Comparative Analysis by Early Stage Development, H2 2016 16 Products under Development by Companies, H2 2016 17 Products under Development by Companies, H2 2016 (Contd..1) 18 Products under Investigation by Universities/Institutes, H2 2016 19 Atrial Fibrillation - Pipeline by ARCA biopharma, Inc., H2 2016 20 Atrial Fibrillation - Pipeline by AstraZeneca Plc, H2 2016 21 Atrial Fibrillation - Pipeline by Bristol-Myers Squibb Company, H2 2016 22 Atrial Fibrillation - Pipeline by Cardiome Pharma Corp., H2 2016 23 Atrial Fibrillation - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 24 Atrial Fibrillation - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016 25 Atrial Fibrillation - Pipeline by Gilead Sciences, Inc., H2 2016 26 Atrial Fibrillation - Pipeline by Laboratoires Pierre Fabre SA, H2 2016 27 Atrial Fibrillation - Pipeline by Nissan Chemical Industries, Ltd., H2 2016 28 Atrial Fibrillation - Pipeline by OMEICOS Therapeutics GmbH, H2 2016 29 Atrial Fibrillation - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 30 Atrial Fibrillation - Pipeline by Xention Limited, H2 2016 31 Assessment by Monotherapy Products, H2 2016 32 Number of Products by Stage and Target, H2 2016 34 Number of Products by Stage and Mechanism of Action, H2 2016 36 Number of Products by Stage and Route of Administration, H2 2016 38 Number of Products by Stage and Molecule Type, H2 2016 40 Atrial Fibrillation - Dormant Projects, H2 2016 78 Atrial Fibrillation - Dormant Projects (Contd..1), H2 2016 79 Atrial Fibrillation - Dormant Projects (Contd..2), H2 2016 80 Atrial Fibrillation - Dormant Projects (Contd..3), H2 2016 81 Atrial Fibrillation - Dormant Projects (Contd..4), H2 2016 82 Atrial Fibrillation - Discontinued Products, H2 2016 83
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.